These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38841591)

  • 1. Association of clinical, imaging and laboratory parameters with adverse effects of glucocorticoid therapy in patients with giant cell arteritis.
    Schweiger L; Hafner F; Meinitzer A; Brodmann M; Dejaco C; Jud P
    Front Med (Lausanne); 2024; 11():1382946. PubMed ID: 38841591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
    Buttgereit F; Dejaco C; Matteson EL; Dasgupta B
    JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
    Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
    Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Patterns, Disease Burden, and Outcomes in Patients with Giant Cell Arteritis and Polymyalgia Rheumatica: A Real-World, Electronic Health Record-Based Study of Patients in Clinical Practice.
    Craig G; Knapp K; Salim B; Mohan SV; Michalska M
    Rheumatol Ther; 2021 Mar; 8(1):529-539. PubMed ID: 33638132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serious adverse effects associated with glucocorticoid therapy in patients with giant cell arteritis (GCA): A nested case-control analysis.
    Wilson JC; Sarsour K; Collinson N; Tuckwell K; Musselman D; Klearman M; Napalkov P; Jick SS; Stone JH; Meier CR
    Semin Arthritis Rheum; 2017 Jun; 46(6):819-827. PubMed ID: 28040244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid glucocorticoid tapering regimen in patients with giant cell arteritis: a single centre cohort study.
    Mensch N; Hemmig AK; Aschwanden M; Imfeld S; Stegert M; Recher M; Staub D; Kyburz D; Berger CT; Daikeler T
    RMD Open; 2023 Jul; 9(3):. PubMed ID: 37460275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic features and glucocorticoid-induced comorbidities in patients with giant cell arteritis and polymyalgia rheumatica in a Dutch and Danish cohort.
    Esen I; Arends S; Dalsgaard Nielsen B; Therkildsen P; Hansen I; van 't Ende A; Heeringa P; Boots A; Hauge E; Brouwer E; van Sleen Y
    RMD Open; 2023 Jan; 9(1):. PubMed ID: 36631159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis.
    Matteson EL; Buttgereit F; Dejaco C; Dasgupta B
    Rheum Dis Clin North Am; 2016 Feb; 42(1):75-90, viii. PubMed ID: 26611552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Leukocyte Dynamics Reveal a Persistent Myeloid Dominance in Giant Cell Arteritis and Polymyalgia Rheumatica.
    van Sleen Y; Graver JC; Abdulahad WH; van der Geest KSM; Boots AMH; Sandovici M; Brouwer E
    Front Immunol; 2019; 10():1981. PubMed ID: 31507597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impacts of glucocorticoid treatment in patients with polymyalgia rheumatica and giant cell arteritis.
    Emamifar A; Ellingsen T; Hermann AP; Hess S; Gerke O; Ahangarani Farahani Z; Syrak Hansen P; Jensen Hansen IM; Thye-Rønn P
    Sci Rep; 2021 Mar; 11(1):6220. PubMed ID: 33737697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adrenal insufficiency in prednisolone-treated patients with polymyalgia rheumatica or giant cell arteritis-prevalence and clinical approach.
    Borresen SW; Thorgrimsen TB; Jensen B; Hilsted L; Bartels EM; Feldt-Rasmussen U; Locht H
    Rheumatology (Oxford); 2020 Oct; 59(10):2764-2773. PubMed ID: 32031663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions.
    Sugihara T; Hasegawa H; Uchida HA; Yoshifuji H; Watanabe Y; Amiya E; Maejima Y; Konishi M; Murakawa Y; Ogawa N; Furuta S; Katsumata Y; Komagata Y; Naniwa T; Okazaki T; Tanaka Y; Takeuchi T; Nakaoka Y; Arimura Y; Harigai M; Isobe M;
    Arthritis Res Ther; 2020 Apr; 22(1):72. PubMed ID: 32264967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subclinical giant cell arteritis increases the risk of relapse in polymyalgia rheumatica.
    De Miguel E; Karalilova R; Macchioni P; Ponte C; Conticini E; Cowley S; Tomelleri A; Monti S; Monjo I; Batalov Z; Klinowski G; Falsetti P; Kane DJ; Campochiaro C; Hočevar A
    Ann Rheum Dis; 2024 Feb; 83(3):335-341. PubMed ID: 37932008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica.
    Braun N; Fritz P; Rieth A; Schroth W; Kimmel M; Biegger D; Zakim D; Alscher MD
    J Rheumatol; 2009 Oct; 36(10):2269-76. PubMed ID: 19684157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral or pulse glucocorticoid use at the onset of giant cell arteritis and its influence on the risk of relapse: a retrospective study.
    Trives-Folguera L; Molina-Collada J; López K; Rivera J; Serrano-Benavente B; Anzola-Alfaro AM; Castrejón I; Álvaro-Gracia JM; Martínez-Barrio J
    Rheumatol Int; 2023 Jul; 43(7):1333-1340. PubMed ID: 37027021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review.
    Raleigh MF; Stoddard J; Darrow HJ
    Am Fam Physician; 2022 Oct; 106(4):420-426. PubMed ID: 36260899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic bone health considerations in giant cell arteritis and polymyalgia rheumatica.
    Low C; Conway R
    Womens Health (Lond); 2023; 19():17455057221147385. PubMed ID: 36627860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between glucocorticoid therapy and incidence of diabetes mellitus in polymyalgia rheumatica and giant cell arteritis: a systematic review and meta-analysis.
    Lai LYH; Harris E; West RM; Mackie SL
    RMD Open; 2018; 4(1):e000521. PubMed ID: 29531778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease Relapses among Patients with Giant Cell Arteritis: A Prospective, Longitudinal Cohort Study.
    Kermani TA; Warrington KJ; Cuthbertson D; Carette S; Hoffman GS; Khalidi NA; Koening CL; Langford CA; Maksimowicz-McKinnon K; McAlear CA; Monach PA; Seo P; Merkel PA; Ytterberg SR;
    J Rheumatol; 2015 Jul; 42(7):1213-7. PubMed ID: 25877501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study.
    Paskins Z; Whittle R; Sultan AA; Muller S; Blagojevic-Bucknall M; Helliwell T; Hider S; Roddy E; Mallen C
    BMC Med; 2018 Jan; 16(1):4. PubMed ID: 29316928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.